WELL:LSE:LSE-Hanetf Icav - Han-Gins Healthcare Innovation Ucits ETF (USD)

ETF | Others |

Last Closing

USD 7.1795

Change

+0.10 (+1.44)%

Market Cap

N/A

Volume

15.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-0.50 (-0.22%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.02 (+0.01%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.16 (-0.87%)

USD 588.35B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.08 (-0.54%)

USD 588.35B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+1.05 (+1.52%)

USD 266.08B
0QZO:LSE 0QZO

+2.10 (+1.92%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.26 (-0.85%)

USD 244.75B
0QZ3:LSE Qualcomm Inc.

+0.88 (+0.51%)

USD 202.26B
0R24:LSE Intel Corp.

-0.03 (-0.12%)

USD 196.14B

ETFs Containing WELL:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.02% 80% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.02% 80% B- 73% C
Trailing 12 Months  
Capital Gain -1.05% 14% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.05% 12% F 29% F
Trailing 5 Years  
Capital Gain -20.36% 12% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.36% 10% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -4.90% 9% A- 20% F
Dividend Return -4.90% 8% B- 19% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.24% 30% F 47% F
Risk Adjusted Return -23.08% 13% F 21% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.